Opportunities in the fertility market with Claire Love
Claire Love, Global Health Industries Advisory Leader at PwC, joins Marissa Plescia to unpack PwC's recent report on the fertility market. She explains why the growth story is far from over, where access still falls short in the US, and how AI, OBGYNs and GLP-1s could reshape the fertility journey. Key Takeaways The fertility market still has tremendous room to grow, driven by people having children later and by preemptive moves like egg freezing. Access is the biggest gap. Countries like Spain and Australia treat a much larger share of the people who need care than the US does. Reproductive endocrinologists are a core supply constraint, and medical schools don't produce enough of them to meet demand. AI in embryo selection and a bigger role for OBGYNs could expand capacity and raise clinic throughput. GLP-1s are sparking a healthy debate among fertility doctors about improving the odds of success before treatment even begins. Links and Resources Host: Marissa Plescia, MedCity News Email: mplescia@medcitynews.com LinkedIn: linkedin.com/in/marissaplescia Keywords fertility market, PwC fertility report, Claire Love PwC, women's health investment, infertility treatment, fertility access, egg freezing, IVF, reproductive endocrinologist shortage, AI embryo selection, fertility clinics, GLP-1 and fertility, state fertility mandates, OBGYN fertility care, femtech, women's health market, menopause market, women-specific oncology, women and Alzheimer's, MedCity FemFwd Episode Highlights [00:00:35 - 00:01:50] Claire explains how PwC defines women's health and why fertility is a human challenge, not just a female one. [00:02:00 - 00:02:40] Later parenthood and egg freezing as the demographic engines of fertility market growth. [00:02:40 - 00:03:20] Why Spain and Australia treat far more of the people who need fertility care than the US. [00:03:20 - 00:03:45] State mandates, supply-side change, and AI as a way past the RE constraint. [00:03:55 - 00:04:25] The biggest surprise: how much further the fertility market still has to go. [00:04:40 - 00:05:50] Medical schools can't produce enough REs, and the roles of OBGYNs and specialists are blending. [00:05:55 - 00:06:25] Fertility has been working with AI for five to 10 years, and better embryo selection could lift throughput. [00:06:30 - 00:07:35] The debate over GLP-1s as a possible first step before fertility treatment. [00:07:55 - 00:09:10] Lessons from PwC's menopause and women-specific oncology reports. [00:09:10 - 00:09:40] Neuroscience is next, since women are 70% of Alzheimer's patients. [00:09:55 - 00:10:15] What success looks like: more awareness, and more investment behind companies filling the gaps.















